Malignant interstitial cell carcinoma of the testis: Report of two cases with steroid synthetic profiles, response to therapy, and review of the literature

Abstract

Two cases of malignant interstitial cell carcinoma of the testis are reported. The first patient had no evidence of a virilizing syndrome. Basal plasma testosterone (T) was decreased, whereas plasma luteinizing hormone, estrone (E1), and androstenedione were elevated. These findings were diagnostic of a defect in T secretion as a result of a partial 17‐hydroxysteroid dehydrogenase deficiency as seen in male pseudohermaphroditism. In the second patient, showing gynecomastia and atrophic testis, endocrine studies revealed high plasma T and estradiol (E2); all measured Δ4 and Δ5 precursors of T were elevated resembling the pattern seen in virilizing adrenal carcinomas. Both patients were treated with radiotherapy without demonstrable effect. Chemotherapy—consisting of a combination of cis‐platinum, vinblastine, and bleomycin; then cyclophosphamide, doxorubicin, and vincristine; and finally o, p′‐DDD—was unsuccessful in reducing tumor bulk. Since malignant Leydig cell carcinomas are rare, this paper reviews the literature and makes recommendations concerning treatment.

Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors

“…Traditional cisplatinum chemotherapy regimens have little impact on TSCST. 2,7 In patients with TSCST and metastasis limited to the retroperitoneum full RPLND is recommended but the risk of recurrence and progression remains high. At diagnosis 2 patients had radiographic evidence of disease limited to the retroperitoneum and each underwent RPLND.…”

“…Most commonly patients present with a painless testicular mass, although symptoms due to excessive hormonal secretion such as gynecomastia may also occur. 2 Together these tumors comprise approximately 4% to 5% of all testicular tumors. 3…”